Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.66 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 3/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525862 | 1.00 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL264362 | 1.00 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| Hydrochloric Acid SCHEMBL28350663 | 0.98 | CTSK (0.64) | CTSKCTSSATMGABRB1GABRB2 | |
| Bromide SCHEMBL8184293 | 0.98 | CTSK (0.64) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL15671568 | 0.94 | CTSK (0.67) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL15671569 | 0.94 | CTSK (0.67) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL3759870 | 0.91 | CTSK (0.56) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL27158950 | 0.91 | CTSK (0.56) | CTSKCTSSATMPPARAPPARG | |
| SCHEMBL16171655 | 0.90 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 | |
| SCHEMBL16174111 | 0.90 | CTSK (0.66) | CTSKCTSSATMGABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790178-B | Preparation method of oxaagoli sodium | 福安药业集团宁波天衡制药有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-104592163-B | A kind of synthetic method of chirality 2-Phenylpyrrolidine | 爱斯特（成都）生物制药有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-104592163-A | Synthetic method of chiral 2-phenylpyrrolidine | ASTATECH CHENGDU BIOPHARM CO LTD | 2015-05-06 | — | — | CN | claimed |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4721737-A1 | USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025243042-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D | THE UNIVERSITY OF LIVERPOOL (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-12435181-B2 | Formulations capable of reacting with or removal of molecular oxygen | LI SHENSHEN (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-4039533-A | CEPHALOSPORINS | PFIZER INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-4039532-A | BACTERICIDES | PFIZER INC. (US) | 1977-08-02 | — | — | US | disclosed |
| US-4012380-A | 7-Acylamino-3-acyl-2(or 3)cephems | ELI LILLY AND COMPANY (US) | 1977-03-15 | — | — | US | disclosed |
| US-3998816-A | 7-[5-N-(n-Butoxyethoxy carbonyl and 2-chloroethoxy carbonyl)-amino] cephalosporins C | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-12-21 | — | — | US | disclosed |
| US-3989685-A | FROM PENICILLIN-1-OXIDE | SHINOGI & CO., LTD. (JA) | 1976-11-02 | — | — | US | disclosed |
| US-3988326-A | Process for N-acylation of 7 amino cephem compounds | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
| US-3968226-A | 3-Heterocyclic thiomethylcephalosporins as antibacterial agents | SMITHKLINE CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
| US-3966719-A | ANTIBACTERIAL | PFIZER INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3947413-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | CTSK 2352/4885CTSS 2855/4885ATM 983/4885 |
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | CTSK 1192/4885CTSS 2671/4885ATM 1532/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | CTSK 3949/4885CTSS 3675/4885ATM 2816/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | CTSK 2406/4885CTSS 1555/4885ATM 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.